Ep181: Claire Mazumdar on a Two-Pronged Attack Against Cancer

Episode Summary

Executive Summary: Claire Mazumdar explains how Bacara Therapeutics built fiserafusp alfa, an EGFR/TGF-beta bifunctional antibody for HPV-negative head and neck cancer, from scientific concept to Phase 1/1B clinical signals. She discusses the science, startup journey, fundraising, ASCO results, market skepticism, and why the company is now advancing a pivotal trial despite a tough biotech environment.

Main Topics: From academic biology to biotech leadership (Priority: 5/5): Mazumdar traces her path from MIT and Stanford to business development and company-building, highlighting how exposure to research, mentors, and business training prepared her to found and lead a biotech company. Why TGF-beta and EGFR were the right biology (Priority: 5/5): The conversation explains the rationale for localizing TGF-beta blockade to the tumor microenvironment using an EGFR-targeted bifunctional antibody, especially in HPV-negative head and neck cancer. Starting Bacara during COVID (Priority: 4/5): Mazumdar describes founding Bacara in early 2020 amid pregnancy, remote work, and pandemic uncertainty, while raising early capital and building a team under difficult conditions. Clinical proof-of-concept and ASCO data (Priority: 5/5): They review Phase 1/1B findings showing durable responses and longer survival in HPV-negative head and neck cancer patients treated with fiserafusp alfa plus pembrolizumab. Investor reaction and public-market skepticism (Priority: 4/5): Despite encouraging biology and clinical data, Wall Street reacted coolly, especially relative to a competing Merus program, illustrating the gap between long-term clinical logic and short-term market sentiment. Capital, execution, and future indications (Priority: 4/5): Bacara's strong financing enables a pivotal Phase II/III trial and exploration of additional tumor subtypes, while Mazumdar emphasizes disciplined prioritization and long-term development. Balancing company-building and family life (Priority: 3/5): Mazumdar discusses family support, dinner-table routines, and the importance of strong teams at home and at work in sustaining a demanding CEO role.

Key Arguments: Bifunctional targeting of EGFR plus TGF-beta is a rational way to address both tumor cells and the immunosuppressive microenvironment in HPV-negative head and neck cancer. Localizing TGF-beta inhibition to the tumor may overcome the failures of older systemic TGF-beta drugs and improve durability of responses. Early human data suggest the approach can produce deeper and more durable responses than expected in a disease with limited frontline options. The most meaningful endpoint is not a short-term landmark but durable overall survival and response duration in the right patient subgroup. Bacara’s trial strategy is biology-driven: HPV-negative disease and CPS 0 patients are more likely to benefit because they are more TGF-beta-driven and immunosuppressed. The company’s strong financing allows it to stay focused on execution and avoid cutbacks while continuing to test broader applications of the asset. Market disappointment reflects short-term comparison dynamics, not necessarily the underlying clinical value of the program. Strong scientific and business training, plus mentorship and team-building, were essential to moving from concept to CEO leadership.

Data Points: First efficacy set: 15 of 28 patients - Phase I data in HPV-negative head and neck cancer; about 54% had significant tumor shrinkage. Overall survival: 21.3 months - Median survival reported for the early head and neck cohort treated with fiserafusp alfa plus pembrolizumab. Treatment response rate with pembrolizumab alone: ~19% - Referenced as the frontline standard-of-care response rate in head and neck cancer. Median overall survival with pembrolizumab alone: 9-12 months - Used to frame the unmet need in HPV-negative recurrent/metastatic head and neck cancer. Duration of response with pembrolizumab responders: ~23-24 months - Illustrates why durable responses matter even when overall response rates are modest. Complete response rate with immunotherapy in head and neck: 3%-5% - Described as the typical benchmark before Bacara's combination data. Potential complete response opportunity with Bacara regimen: ~1 in 5 patients - Mazumdar said investigators were seeing complete responses in roughly 20% of patients in the early dataset. IPO proceeds: $362 million - Bacara raised this amount in its September 2024 IPO. Cash runway: Into the first half of 2029 - From the company's most recent quarterly report. Series B financing: $110 million - Raised to support clinical development and expansion. Series C financing: Just north of $160 million - Closed as Mazumdar was giving birth to her second child. Early clinical cohort for ASCO analysis: 28 patients with at least two years of follow-up - Subset analyzed for durable follow-up data at ASCO. Population size in recurrent/metastatic head and neck: 20,000-30,000 patients - Discussed as the frontline recurrent/metastatic market size. Locally advanced head and neck population: ~60,000 - Referenced as a broader disease setting with additional opportunity. CPS 0 subset size: ~15% of patients - A chemo-containing, pembrolizumab-unapproved subgroup Bacara may target. Dosing interval: Weekly; with an every-2-week cohort being explored - Current and potential future dosing schedule for fiserafusp alfa.

Pivotal Quotes: "I think cancer is this disease that keeps one upping you." — Claire Mazumdar: Explaining why biology and cancer research captured her interest early. "We really believe this TGF beta would help synergize with the PD-1 and go after the tumor microenvironment and penetrate the tumor." — Claire Mazumdar: Summarizing the scientific thesis behind Bacara's combination strategy. "I think if we're successful, it's about building, you know, and commercializing this molecule and showing its potential not only in head and neck, but in other tumor types." — Claire Mazumdar: Describing the company's long-term vision beyond the lead indication.

Implications: The interview shows how rigorous biology, patient selection, and long timelines can drive real oncology innovation even when public markets are skeptical. If validated, Bacara could expand immunotherapy benefit in hard-to-treat solid tumors.